Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of thiazolidinedione amide on insulin resistance, c-reactive protein and endothelial function in young women with polycystic ovary syndrome

Wen-Yu Zhong^1,2, Hui Peng³, Hua Li², Hui Shang², Yong-Qing Wei², Zheng-Hui Fang², Xing-Bo Zhao¹

¹Department of Obstetrics & Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021; ²Department of Obstetrics & Gynecology; ³Department of Pediatrics, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, 250013, China.

For correspondence:- Xing-Bo Zhao Email: zhaoxingbo458@gmail.com Tel:+8653187938911

Received: 18 May 2015 Accepted: 31 October 2015 Published: 27 December 2015

Citation: Zhong W, Peng H, Li H, Shang H, Wei Y, Fang Z, et al. Effect of thiazolidinedione amide on insulin resistance, c-reactive protein and endothelial function in young women with polycystic ovary syndrome. Trop J Pharm Res 2015; 14(12):2287-2292 doi: 10.4314/tjpr.v14i12.19

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of thiazolidinedione amide (TZDA) treatment on high-sensitivity C-reactive protein (hsCRP) levels and endothelial dysfunction in patients with polycystic ovary syndrome (PCOS).

Methods: Twenty five women (mean age 24.7 ± 3.9 years; mean body mass index (BMI), 23.2 ± 4.0 kg/m²) with PCOS were treated with 15 µM TZDA daily for 12 months. Serum levels of testosterone, leutenizing hormone (LH), follicle stimulating hormone (FSH), sex hormone-binding globulin (SHBG), insulin and hsCRP were measured. BMI, hirsutism scores and insulin sensitivity indices were also calculated prior to and after TZDA treatment. Brachial artery responses to stimuli was used to measure arterial endothelium and smooth muscle function prior to and after the treatment.

Results: TZDA treatment caused a significant (p < 0.05) decrease in serum testosterone from 93.1 ± 40.3 to 54.8 ± 19.5 ng/dl and fasting insulin concentration from 11.9 ± 6.8 to 9.23 ± 5.13 U/mL. Insulin resistance index significantly (p < 0.05) improved and hirsutism score decreased significantly from 11.6 ± 2.0 to 6.8 ± 2.0. BMI, waist circumference, serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, FSH and LH levels remained almost unchanged. Twenty-four of the women reverted to regular menstrual cycles. SHBG levels showed a significant (p < 0.05) increase from 24.8 ± 9.5 to 49.1 ± 13.5 nmol/L after TZDA treatment. Serum hsCRP levels decreased (p < 0.05) from 0.25 ± 0.1 to 0.09 ± 0.02 mg/dL while endothelium-dependent vascular responses significantly improved (p < 0.05) following TZDA treatment (9.9 ± 3.9 vs 16.4 ± 5.1%).

Conclusion: TZDA treatment improves insulin sensitivity, decreases androgen production and improves endothelial dysfunction in young women with PCOS.

Keywords: Thiazolidinedione amide, Insulin sensitivity, Endothelial dysfunction, Polycystic ovary syndrome